Results 161 to 170 of about 57,090 (240)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 997-1004, April 2026.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

A Case Series of Sudden Death in Children Aged 12 Months to 4 Years From LPIN1 Deficiency and PPA2 Deficiency in Queensland

Journal of Paediatrics and Child Health, EarlyView.
Sophie Manoy, Sally Smith, Marita Smith, Catherine Atthow, Janette Spicer, Matthew Lynch, Michelle Lipke, Julie A. McEniery, David Coman, Anita Inwood, Jim McGill, Carolyn Bursle   +11 more
wiley   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

MyD88 Deficiency Protects Mice From Experimental Autoimmune Encephalomyelitis by Influencing Both Dendritic Cells and T Cells

Immunology, Volume 177, Issue 4, Page 784-797, April 2026.
This study investigates the role of MyD88 in dendritic cells (DCs) and T cells during experimental autoimmune encephalomyelitis (EAE). We found that MyD88 is highly expressed in DCs and CD4+ T cells in people with multiple sclerosis, and its deficiency impairs DC maturation, reduces pro‐inflammatory cytokine production, weakens DC–T cell interactions ...
Wen Si, Gaochen Zhu, Qianling Jiang, Xin Ma, Guan Yang   +4 more
wiley   +1 more source

Fulminant myocarditis [PDF]

BMJ Case Reports, 2018
Takatsugu Segawa, Yoh Arita, Tomomi Akari, Shinji Hasegawa   +3 more
openaire   +2 more sources

Durvalumab combined with concurrent chemoradiotherapy in patients with limited‐stage small cell lung cancer: A prospective, single‐arm, phase 2 clinical trial

Cancer, Volume 132, Issue 6, 15 March 2026.
Abstract Background The current standard treatment for limited‐stage small cell lung cancer (LS‐SCLC) is concurrent chemoradiotherapy (cCRT) plus consolidation immunotherapy, with or without prophylactic cranial irradiation (PCI). However, it remains unknown whether administering immunotherapy concurrently with chemoradiotherapy confers additional ...
Chunyang Song, Xiaohan Zhao, Shuguang Li, Xuehan Guo, Xueyuan Zhang, Xiaobin Wang, Youmei Li, Ke Yan, Jingwei Su, Jinrui Xu, Shuchai Zhu, Wenbin Shen   +11 more
wiley   +1 more source

Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide‐Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Background Cyclophosphamide (CY) is associated with potentially fatal cardiotoxicity, yet no electrocardiographic indices have been established for early detection of CY‐induced cardiomyopathy. This study aimed to determine whether corrected QT interval (QTc) prolongation can predict early onset of CY‐related cardiac dysfunction in pediatric ...
Junpei Kawamura, Kentaro Ueno, Takuro Nishikawa, Yoshihiro Takahashi, Koji Nakae, Yasuhiro Okamoto   +5 more
wiley   +1 more source

Clinicopathologic and molecular landscape of villitis of unknown etiology: insights from a large‐scale case–control study in PR China

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Villitis of unknown etiology (VUE) is a chronic placental inflammatory lesion characterized by lymphohistiocytic infiltration and destruction of villous architecture in the absence of infection. Although VUE is well recognized for its association with fetal growth restriction and adverse pregnancy outcomes, its clinicopathologic correlates and
Meiling Wang, Xiaorong Sun, Huayan Ren, Fengchun Gao, Xiangyu Sun, Chang Lu, Yanxue Yin, Juan Li, Chengquan Zhao   +8 more
wiley   +1 more source

Targeting Microglial CD49a Inhibits Neuroinflammation and Demonstrates Therapeutic Potential for Parkinson's Disease

Advanced Science, Volume 13, Issue 13, 3 March 2026.
This study shows that integrin receptor CD49a (Itga1 gene) is significantly upregulated in hyperactivated microglia and microglia‐specific knockdown of Itga1 rescues neuroinflammation and neurodegeneration in a chronic Parkinson's disease (PD) model by targeting PGAM5‐mediated mitochondrial dysfunction and NLRP3 activation. Targeted inhibition of CD49a
Huanpeng Lu, Yunmin Zhu, Xi Wang, Zelin Wu, Zijian Xu, Rongqing Chen, Yanwu Guo   +6 more
wiley   +1 more source